Mergers & Acquisitions ·
On June 28, 2026, Pacira BioSciences entered into a Stock and Asset Purchase Agreement to divest its wholly owned…
PCRXPacira BioSciences, Inc.
On June 28, 2026, Pacira BioSciences entered into a Stock and Asset Purchase Agreement to divest its wholly owned subsidiary, Pacira CryoTech, and assets related to iovera handheld cryoanalgesia devices to Zimmer, Inc. (a subsidiary of Zimmer Biomet). The transaction includes an upfront payment of $70.0 million, with potential contingent revenue-based milestones of up to $70.0 million through December 31, 2031, for a total potential value of $140.0 million. The deal involves the transfer of 66 employees, representing approximately 8% of Pacira's workforce. The transaction is expected to close in the third quarter of 2026. Pacira BioSciences is a pharmaceutical company that develops and commercializes non-opioid pain management products.